Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619000575134
Ethics application status
Approved
Date submitted
1/04/2019
Date registered
12/04/2019
Date last updated
3/03/2022
Date data sharing statement initially provided
12/04/2019
Date results information initially provided
3/03/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
Clinical Trial of PRAX-114 to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy in Participants with Major Depressive Disorder
Scientific title
A Phase 2 Clinical Trial of PRAX-114 to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy in Participants with Major Depressive Disorder
Secondary ID [1] 297523 0
PRAX-114-202
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Depression 311732 0
Condition category
Condition code
Mental Health 310359 310359 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Part A (inpatient and outpatient) and Part B (outpatient only): PRAX-114 60mg orally once daily for 14 days
Part C: PRAX-114 60mg orally once daily for 27 days
Intervention code [1] 313762 0
Treatment: Drugs
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 319229 0
Safety and tolerability of PRAX-114 will be assessed through an integrated analysis of the following endpoints: patient and clinician-reported adverse events, physical exams, vital signs, clinical laboratory results, electrocardiogram (ECG), Columbia-Suicide Severity Rating Scale (C-SSRS), and Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S)
Timepoint [1] 319229 0
Part A: Baseline, Day 2 to Day 8, Day 15, Day 21 and Day 28
Part B: Baseline, Day 4, Day 8, Day 15, Day 21 and Day 28
Part C: Baseline, Day 8, Day 15, Day 21, Day 28, Day 35 and Day 42
Primary outcome [2] 319230 0
Pharmacokinetics will be performed by LC/MS quantification of PRAX-114 levels in plasma. Parameters include plasma concentrations and accumulation ratios.
Timepoint [2] 319230 0
Part A: Baseline, Daily Day 2 to Day 7, Day 15
Part B: Baseline, Day 4, Day 8, Day 15
Part C: Baseline, Day 8, Day 15, Day 21, Day 28, Day 42
Secondary outcome [1] 367388 0
The efficacy of PRAX-114 as an adjunctive antidepressant to standard of care will be assessed through an integrated analysis of the following endpoints: changes in Hamilton Depression Rating Scale (HAM-D), Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression (CGI), Symptoms of Depression Questionnaire (SDQ), Pittsburgh Sleep Quality Index (PSQI).
Timepoint [1] 367388 0
Part A: Baseline, Day 2 to Day 8, Day 15, Day 21, and Day 28,
Part B: Baseline, Day 4, Day 8, Day 15, Day 21, and Day 28
Part C: Baseline, Day 8, Day 15, Day 21, Day 28, Day 35, and Day 42

Eligibility
Key inclusion criteria
For Part A:
- Male or females between the ages of 18 and 65 years
- Clinical diagnosis of major depressive disorder (MDD)
- Chronic medications or interventions must be stable for at least 4 weeks prior to Screening and remain stable throughout the clinical trial
- Willing to comply with the protocol (including inpatient stay)

For Part B:
- Females 40 years of age or older with irregular menses
- Historical self-report of vasomotor symptoms
- Clinical diagnosis of major depressive disorder (MDD)
- Chronic medications or interventions must be stable for at least 4 weeks prior to Screening and remain stable throughout the clinical trial
- Willing to comply with the protocol

For Part C:
- Male or females between the ages of 18 and 65 years
- Clinical diagnosis of major depressive disorder (MDD)
- Chronic medications or interventions must be stable for at least 4 weeks prior to Screening and remain stable throughout the clinical trial
- Willing to comply with the protocol
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Clinically significant unstable medical or psychiatric condition, other than MDD
- History of treatment resistant depression (failed 3 adequate trials of antidepressant therapy)
- History of a suicide attempt in last 2 years
- History of bipolar disorder
- History of a psychotic episode in last 2 years
- History of alcohol abuse in last 2 years
- History of substance abuse in last 2 years
- History of seizures in last 5 years

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
15/04/2019
Actual
21/05/2019
Date of last participant enrolment
Anticipated
Actual
29/04/2021
Date of last data collection
Anticipated
Actual
29/04/2021
Sample size
Target
60
Accrual to date
Final
52
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 302083 0
Commercial sector/Industry
Name [1] 302083 0
Praxis Precision Medicines Australia, Pty Ltd
Country [1] 302083 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Praxis Precision Medicines Australia, Pty Ltd
Address
Tower Two Collins Square, Level 36
727 Collins Street Docklands Vic 3008
Country
Australia
Secondary sponsor category [1] 301900 0
None
Name [1] 301900 0
Address [1] 301900 0
Country [1] 301900 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 302762 0
Bellberry Human Research Ethics Committees
Ethics committee address [1] 302762 0
123 Glen Osmond Rd
Eastwood SA 5063
Ethics committee country [1] 302762 0
Australia
Date submitted for ethics approval [1] 302762 0
Approval date [1] 302762 0
14/12/2018
Ethics approval number [1] 302762 0

Summary
Brief summary
This is a clinical trial of PRAX-114 to assess the safety, tolerability, PK, and efficacy in participants with moderate to severe MDD. Each participant will complete 3 study periods: Screening, Treatment Period (14 days) and Safety Follow-up.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 91310 0
Prof Paul Fitzgerald
Address 91310 0
Epworth Camberwell
888 Toorak Road
Camberwell, 3124, VIC
Country 91310 0
Australia
Phone 91310 0
+61 3 98054827
Fax 91310 0
Email 91310 0
[email protected]
Contact person for public queries
Name 91311 0
Bernard Ravina
Address 91311 0
Praxis Precision Medicines
One Broadway
Cambridge, MA 02142
Country 91311 0
United States of America
Phone 91311 0
+1 617 300 8460
Fax 91311 0
Email 91311 0
[email protected]
Contact person for scientific queries
Name 91312 0
Bernard Ravina
Address 91312 0
Praxis Precision Medicines
One Broadway
Cambridge, MA 02142
Country 91312 0
United States of America
Phone 91312 0
+1 617 300 8460
Fax 91312 0
Email 91312 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Individual participant data will not be shared


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Other filesNo https://investors.praxismedicines.com/news-release... [More Details]
Conference abstractNo https://doi.org/10.1038/s41386-021-01236-7

Documents added automatically
No additional documents have been identified.